John De Koning

atbtherapeutics is a pioneering biopharmaceutical company building a new line of attack against cancer. atbtherapeutics has developed the atbody; a game-changer biologic format designed to broaden the therapeutic window of antibody-based therapies. Only our proprietary and versatile plant-based atbiofarm technology enables single-step manufacturing of our novel class of therapeutic atbodies. The resulting therapeutics offer a novel mechanism of action, avoiding major cancer cell resistance, and provide a promising, life-changing therapy for hard-to-treat and refractory cancer.

Tubulis® generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Our goal is to expand the therapeutic potential of antibody drug conjugates (ADCs) ushering in a new era and delivering better outcomes for patients. We will advance a range of conjugates, unlimited by indication, using our own discovery capabilities and by solving development challenges for partners with both antibody and chemical assets.

With offices in Seattle, Wash., and Irvine, Calif., Visus Therapeutics is a clinical-stage pharmaceutical company focused on developing innovative ophthalmic therapies to improve vision for people around the world. The company is developing novel miotic formulations for a once-daily eye drop to correct the loss of near vision associated with presbyopia. In parallel, Visus Therapeutics is focused on advancing its pipeline of early-stage ophthalmic product candidates with applications in ocular surface disease, glaucoma and age-related macular degeneration. Additionally, Visus Therapeutics has entered into a worldwide exclusive licensing agreement with DelSiTech Ltd, a leader in advanced, biodegradable, silica-based, controlled-release materials, to develop novel drug delivery technology that can help optimize the clinical benefit of ophthalmic therapies.

Developing next generation technologies for precision medicine and drug discovery.

VarmX (www.varmx.com) is a young Leiden based biotech company that is focusing on the development of therapies in the field of hemostasis and thrombosis. Originally a spin-off from the Leiden University Medical Center (LUMC), our mission is to develop and manufacture therapeutic proteins to restore hemostasis. Our lead compound, VMX-C001, is intended to safely and effectively restore hemostasis in case of bleeding or emergency surgery in patients taking so-called oral factor Xa inhibitors. The VarmX program has gained significant interest in the investment community and a very successful Series B financing round of €32 mill. was closed in 2020. This round was followed by a Series B2 round of €32 mill. in May 2023 allowing the company to further progress the lead program towards Investigational New Drug (IND) approval and prepare for pivotal trials.

XyloCor Therapeutics is a development-stage, biotechnology company dedicated to developing first-in-class gene therapies for patients with unmet medical need in cardiovascular disease.

Aelin Therapeutics is a privately held Belgian biotechnology company, pioneering a novel modality in drug development. Using our Pept-in platform technology, we can create a completely new class of antibiotics and first-in-class therapeutics against high-value undruggable human targets. The technology harnesses the power of protein aggregation to specifically induce functional knockdown of a target protein.

GTX medical is a spin-off from the Swiss Tech Institute (EPFL, Ecole Polytechnique Fédérale de Lausanne, Switzerland) translating for human use a fundamentally new treatment paradigm that restored voluntary locomotion in fully paralyzed animals with a success rate close to 100%. Our therapeutic approach provides an environment enabling the brain to repair itself. The company is developing an implantable stimulation system and a 3D overground Body Weight Support training program to rehabilitate individuals with spinal cord injury.

Driving discovery and solving challenges for partners across LNP formulation and RNA chemistry | www.etherna.be | www.ethernamanufacturing.com We are an RNA technology company, with over 30 years’ experience, offering professional partnership to pharma and biotech with an emerging or established interest in RNA therapeutics. Our expert team supports start-up, early stage and late stage projects by using our proprietary platforms across RNA chemistry, LNP formulation and Process Technology, to drive new pipeline development or resolve manufacturing challenges for our partners.

ONWARD is a medical technology company creating innovative therapies to restore movement, function, and independence in people with spinal cord injuries. ONWARD’s work builds on more than a decade of basic science and preclinical research conducted at the world’s leading neuroscience laboratories. ARC Therapy, which can be delivered by implantable (ARC-IM) or external (ARC-EX) systems, is designed to deliver targeted, programmed spinal cord stimulation to restore movement and other functions in people with spinal cord injury, ultimately improving their quality of life. ONWARD has received nine Breakthrough Device Designations from the U.S. FDA encompassing both ARC-IM and ARC-EX. ARC-EX is an external, non-invasive platform consisting of a wearable stimulator and wireless programmer. Positive top-line data were reported in September 2022 from the company’s first pivotal study, called Up-LIFT, evaluating the ability of transcutaneous ARC Therapy to improve upper extremity strength and function. The company is now preparing marketing approval submissions for the U.S. and Europe. ARC-IM consists of an implantable pulse generator and lead placed near the spinal cord. The company completed its first-in-human use of the ARC-IM neurostimulator in May 2022. ONWARD is headquartered in Eindhoven, the Netherlands. It maintains a Science and Engineering Center in Lausanne, Switzerland, and has a growing U.S. presence in Boston, Massachusetts. The company has an academic partnership with .NeuroRestore, a collaboration between the Swiss Federal Institute of Technology (EPFL) and Lausanne University Hospital (CHUV).

Merus is developing best-in-class therapeutics to treat and potentially cure cancer patients. Our most advanced development programs use the Biclonics® format. Biclonics® are capable of simultaneously attacking tumors in multiple ways. For example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways. Working at Merus offers opportunity to grow and develop a career that offers both individual and company success. You have the chance to make an impact within the oncology field by being part of the development of bispecific antibody therapies (Biclonics®) to help fight cancer. Merus’ Head Quarters are located in The Netherlands, with offices in the US and collaborators around the world. As of 2016 we are listed on NASDAQ and over a period of 10 years we have several candidate drugs in clinical trials. For more information, please visit www.merus.nl Read our Community Guidelines: https://merus.nl/community-guidelines/

Small biotech company that specializes in developing new invitro diagnostic devices

argenx is a global immunology company committed to improving the lives of people living with severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx is translating immunology breakthroughs into a world-class portfolio of novel antibody-based medicines.

At SkylineDx, we live to make a difference. It is our mission to improve a patient’s quality of life by enabling them to benefit from personal insights at the genomic level of their disease. That means we are continuously innovating the world of gene signature-based diagnostic testing. Genes are responsible for making us who we are. It can determine our features such hair and eye color, skin tone, or even height. Although we know our genetic make-up is similar to one another, each individual is vastly unique. “No two humans are alike.” And while most agree on the quote above, the contrary is being practiced in disease treatment today. When a patient gets a cancer diagnosis, he or she is treated, more or less, the same as other patients with the same type of cancer. For decades we have known, but were not able to determine why patients with the same diagnosis respond differently to the same treatment. Today, after years of genetic research, we know that like humans, no two cancer cells are alike. And for that reason, we now know cancer treatments should differ case by case, because cancer cells are inherently different. At SkylineDx, we have a team of experts with the knowledge and capability to collaborate with highly respected physicians and patients advocates. Together we work to achieve the same multi-disciplinary goal: to give physicians the genetic tools to better guide the most affective treatment plan for their patients. This principle of individualized treatment plans is called personalized- or precision medicine and is extremely important for the patient. With the right personalized treatment, at the right moment, the patient can avoid side effects from over or undertreatment, which means less hospitalization, complications, medications, and ultimately better quality of life.

BioMarin leads the biotechnology industry in delivering therapies for chronic and degenerative genetic conditions that reduce patients' quality of life and shorten life spans. We target diseases that lack effective therapies and affect relatively small numbers of patients, many of whom are children. As we enter 2014, BioMarin will continue to focus on advancing therapies that are the first or best of their kind and make a big difference in improving patients' lives.

atbtherapeutics is a pioneering biopharmaceutical company building a new line of attack against cancer. atbtherapeutics has developed the atbody; a game-changer biologic format designed to broaden the therapeutic window of antibody-based therapies. Only our proprietary and versatile plant-based atbiofarm technology enables single-step manufacturing of our novel class of therapeutic atbodies. The resulting therapeutics offer a novel mechanism of action, avoiding major cancer cell resistance, and provide a promising, life-changing therapy for hard-to-treat and refractory cancer.

Tubulis® generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Our goal is to expand the therapeutic potential of antibody drug conjugates (ADCs) ushering in a new era and delivering better outcomes for patients. We will advance a range of conjugates, unlimited by indication, using our own discovery capabilities and by solving development challenges for partners with both antibody and chemical assets.

EQT Life Sciences, formerly LSP, is one of Europe’s largest and most experienced healthcare investors, targeting innovative life sciences and health care companies.

With offices in Seattle, Wash., and Irvine, Calif., Visus Therapeutics is a clinical-stage pharmaceutical company focused on developing innovative ophthalmic therapies to improve vision for people around the world. The company is developing novel miotic formulations for a once-daily eye drop to correct the loss of near vision associated with presbyopia. In parallel, Visus Therapeutics is focused on advancing its pipeline of early-stage ophthalmic product candidates with applications in ocular surface disease, glaucoma and age-related macular degeneration. Additionally, Visus Therapeutics has entered into a worldwide exclusive licensing agreement with DelSiTech Ltd, a leader in advanced, biodegradable, silica-based, controlled-release materials, to develop novel drug delivery technology that can help optimize the clinical benefit of ophthalmic therapies.

Developing next generation technologies for precision medicine and drug discovery.